Trial Profile

An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; XL 309 (Primary)
Indications Advanced breast cancer; Male breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors InSilico Medicine

13 Mar 2025 Planned number of patients changed from 377 to 425.
12 Jan 2025 According to an Exelixis Inc. media release, company plans to present data from the XL309 program at a scientific meeting in 2025.
26 Apr 2024 Planned number of patients changed from 66 to 377.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com